Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of HyperAcute-Renal (HAR) Immunotherapy In Patients With Metastatic Renal Cell Cancer

NCT02035358 is registered in ClinicalTrials.gov with NewLink Genetics Corporation as lead sponsor.

NCT NCT02035358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02035358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of HyperAcute-Renal (HAR) Immunotherapy In Patients With Metastatic Renal Cell Cancer
Lead sponsor
NewLink Genetics Corporation
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2015
Completion date
January 12, 2021
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic clear-cell renal cancer, metastatic kidney cancer, metastatic renal cell carcinoma, recurrent renal cell carcinoma, refractory renal cell carcinoma